S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NYSE:MRK

Merck & Co., Inc. Competitors

$80.98
-0.20 (-0.25 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$80.76
Now: $80.98
$81.43
50-Day Range
$79.29
MA: $81.83
$85.00
52-Week Range
$65.25
Now: $80.98
$89.66
Volume9.00 million shs
Average Volume9.90 million shs
Market Capitalization$204.88 billion
P/E Ratio17.92
Dividend Yield3.20%
Beta0.43

Competitors

Merck & Co., Inc. (NYSE:MRK) Vs. JNJ, PFE, LLY, ABBV, BMY, and ZTS

Should you be buying MRK stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Merck & Co., Inc., including Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Zoetis (ZTS).

Merck & Co., Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Merck & Co., Inc. and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
Johnson & Johnson031002.77

Merck & Co., Inc. presently has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Johnson & Johnson has a consensus price target of $166.6923, suggesting a potential upside of 1.92%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Johnson & Johnson.

Profitability

This table compares Merck & Co., Inc. and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Johnson & Johnson21.01%34.64%13.40%

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years.

Earnings & Valuation

This table compares Merck & Co., Inc. and Johnson & Johnson's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60
Johnson & Johnson$82.06 billion5.25$15.12 billion$8.6818.84

Johnson & Johnson has higher revenue and earnings than Merck & Co., Inc.. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Johnson & Johnson on 9 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pfizer and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010402.29
Merck & Co., Inc.021202.86

Pfizer currently has a consensus price target of $40.0714, suggesting a potential upside of 9.63%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Pfizer.

Profitability

This table compares Pfizer and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Valuation and Earnings

This table compares Pfizer and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.93$16.27 billion$2.9512.39
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60

Pfizer has higher revenue and earnings than Merck & Co., Inc.. Pfizer is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Pfizer on 11 of the 16 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041012.80
Merck & Co., Inc.021202.86

Eli Lilly and currently has a consensus price target of $179.5714, suggesting a potential downside of 12.89%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Eli Lilly and.

Profitability

This table compares Eli Lilly and and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

Eli Lilly and pays an annual dividend of $2.96 per share and has a dividend yield of 1.4%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Eli Lilly and pays out 49.0% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Valuation and Earnings

This table compares Eli Lilly and and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion8.83$8.32 billion$6.0434.13
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60

Merck & Co., Inc. has higher revenue and earnings than Eli Lilly and. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eli Lilly and has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Eli Lilly and on 10 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AbbVie and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie141602.71
Merck & Co., Inc.021202.86

AbbVie currently has a consensus price target of $112.50, suggesting a potential upside of 1.48%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than AbbVie.

Profitability

This table compares AbbVie and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.7%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation and Earnings

This table compares AbbVie and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.88$7.88 billion$8.9412.40
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60

Merck & Co., Inc. has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats AbbVie on 9 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.0%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Analyst Recommendations

This is a summary of recent ratings and price targets for Bristol-Myers Squibb and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb041012.80
Merck & Co., Inc.021202.86

Bristol-Myers Squibb currently has a consensus price target of $74.2667, suggesting a potential upside of 15.04%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Bristol-Myers Squibb.

Profitability

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.59$3.44 billion$4.6913.77
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60

Merck & Co., Inc. has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Bristol-Myers Squibb on 13 of the 17 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Volatility and Risk

Zoetis has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Zoetis and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis08812.59
Merck & Co., Inc.021202.86

Zoetis currently has a consensus price target of $161.1429, suggesting a potential downside of 1.34%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 17.75%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Zoetis.

Profitability

This table compares Zoetis and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
Merck & Co., Inc.24.33%53.83%16.83%

Valuation & Earnings

This table compares Zoetis and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion12.40$1.50 billion$3.6444.87
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Zoetis pays out 27.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Zoetis on 9 of the 17 factors compared between the two stocks.


Merck & Co., Inc. Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.3$163.55-1.1%$430.55 billion$82.06 billion25.72Upcoming Earnings
News Coverage
Pfizer logo
PFE
Pfizer
2.7$36.55-0.2%$203.16 billion$51.75 billion23.58Analyst Report
Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
1.9$206.14-1.8%$197.19 billion$22.32 billion33.68Upcoming Earnings
Analyst Upgrade
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$110.86-0.4%$195.72 billion$33.27 billion23.44Analyst Revision
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$64.56-0.6%$146.08 billion$26.15 billion-586.86
Zoetis logo
ZTS
Zoetis
1.8$163.33-0.7%$77.63 billion$6.26 billion48.47Ex-Dividend
Royalty Pharma logo
RPRX
Royalty Pharma
1.4$51.16-1.4%$19.86 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$77.73-0.4%$17.16 billion$1.30 billion21.24Insider Selling
News Coverage
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$168.65-1.7%$9.40 billion$2.16 billion53.20Gap Up
Perrigo logo
PRGO
Perrigo
2.4$43.29-0.3%$5.91 billion$4.84 billion-721.38
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$28.06-0.3%$3.26 billion$306.49 million31.53Analyst Downgrade
Insider Selling
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$16.56-0.6%$2.97 billion$114.62 million-6.68
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$67.86-2.5%$2.95 billion$421.03 million23.89Analyst Report
Analyst Revision
News Coverage
Endo International logo
ENDP
Endo International
1.4$6.93-1.7%$1.60 billion$2.91 billion-10.19Analyst Report
Analyst Revision
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$29.94-5.3%$1.58 billion$392.76 million12.42News Coverage
Gap Up
Omeros logo
OMER
Omeros
1.2$19.67-5.3%$1.21 billion$111.81 million-8.26Analyst Report
Insider Selling
Unusual Options Activity
Analyst Revision
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.30-5.0%$1.07 billion$3.65 million-2.03Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$4.14-1.7%$418.60 million$111.39 million29.57
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$6.66-4.7%$303.97 million$16.54 million-2.71Gap Up
Lannett logo
LCI
Lannett
2.0$6.73-1.9%$280.64 million$545.74 million-9.35News Coverage
Gap Up
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$5.88-1.0%$194.17 million$15.96 million-3.56News Coverage
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.30-2.4%$49.56 million$47.53 million-15.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.